AMAM earnings

Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM". "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company and is an important step that will help facilitate our mission to di

- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx to host a conference call today at 5:00 p.m. EST / 2:00 p.m. PST - SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company's cash runway, pipeline near term v

SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company's strategic review of its development pipeline. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.ambrx.com. To access the call by phone, please use the reg

- Conference Call Scheduled for Tuesday, April 26, 2022 at 4:30 p.m. ET - Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that the company will release full year 2021 financial results on Tuesday April 26, 2022 after the close of market. Ambrx will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (844) 200-6205 for domestic callers, or (929) 526-1599 for in